Forward P/S Multiple: Nuwellis (NUWE)

Nuwellis, Inc. - graphic logo of issuer NUWE

Nuwellis, Inc. (NUWE) management is pursuing operating profit by implementing its systems in clinics. Analyzing the chart on GURU.Markets, we find that the forward P/S ratio reflects revenue valuation dynamics, where 0.30 marks a new level. AI-driven Aquapheresis systems for cardiac therapy serve as the foundation, although liquidity risks and dependence on insurance reimbursements constrain the company's growth.

nuwellis.com - NUWE Market Cap to Projected Revenue (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Nuwellis, Inc. (NUWE)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:NUWE (CHF Solutions)
Product sample of Nuwellis Corp

Nuwellis, Inc. (NUWE) maintains significant pricing power in the intensive care segment due to the uniqueness of its Aquadex systems, rendering the company's revenue resilient to market volatility. By analyzing the forward P/S trend, an investor assesses the ratio of current market capitalization to expected annual sales, which helps determine the asset's degree of overvaluation and confirms whether the business's market value is justified relative to its future cash flows.

Who Nuwellis, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom CGM DXCM|Penumbra Corp (PEN) - Market Cap to Future Revenue Ratio|Novanta Inc - Forward P/S Multiple|HAE (Haemonetics Corporation) - Market Cap to Projected Revenue|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED Inc.) - Forward P/S Multiple|Pulse Corp (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward P/S Multiple picardmedical.com (PMI)|Forward P/S Multiple SRDX (surmodics.com)|Forward P/S Multiple Senseonics Holdings, Inc. SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (Sanuwave Health Inc) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Outset Medical OM|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LENSAR Inc. LNSR|Price-to-Projected Revenue Ratio AVITA Medical Inc. (RCEL)|Profound Medical Corporation (PROF) - Projected Price to Revenue|Baird Medical Investment Holdings - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP Medical EDAP|Apyx Medical Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical ICCM|Pulmonx (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio Corp)|Price-to-Projected Revenue Ratio cytosorbents.com|Forward Price-to-Revenue Multiple Sensus Healthcare, Inc. (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio vicarioussurgical.com RBOT|IINN: Market Cap to Projected Revenue|ICU - Price-to-Projected Revenue Ratio|iridex.com - Price to Expected Revenue Ratio|INBS: Forward P/S Multiple|XAIR (Beyond Air Inc) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Profusa, Inc.|SSKN (strataskinsciences.com) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple GCTK (GlucoTrack Inc.)|nanovibronix.com - Market Cap to Projected Revenue|venusconcept.com - Forward Price-to-Revenue Multiple|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Projected Price to Revenue Avinger, Inc (AVGR)|BSGM: Forward P/S Multiple|Cutera (CUTR) - Forward P/S Multiple|KNW (Know Labs) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Inari Medical (NARI)|Price-to-Projected Revenue Ratio nevro.com (NVRO)|RSLS (ReShape Lifesciences, Inc.) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical)